8 min. read

New Teladongo merger details. Pear’s acquisitive study strategy.

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Issue 068

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last week I wrote about Amwell's IPO filing and the possible longterm repercussions of Amazon's move into voice biomarkers via its first wearable device, Halo. Here's what's happening this week:

  • Teladoc-Livongo revealed more information about their multi-billion dollar merger in a lengthy government filing -- more on that below.
  • European tech site Sifted rounded up 15 digital health startups that have applied (or are in the process of applying) for reimbursement in Germany under that country's new digital health law.
  • One of mySugr's four founders, Frank Westermann, who was also the longtime CEO, announced he has left Roche, which acquired mySugr in 2017. He will continue investing and advising health startups post-mySugr.
  • Sunovion Pharmaceuticals is looking to hire a Senior Director

Recent Articles